Stock data
Outlook Therapeutics, Inc. (OTLK)
Outlook Therapeutics, Inc. (OTLK) reported revenue of US$1.41M and net income of -US$62.42M for fiscal 2025. The figures below come from the company's SEC filings.
Annual results
Data as of 2025-09-30
| Fiscal year | Revenue | Gross profit | Operating income | Net income | Diluted EPS |
|---|---|---|---|---|---|
| 2025 | US$1.41M | US$0.06M | -US$67.06M | -US$62.42M | — |
| 2024 | — | — | -US$71.70M | -US$75.37M | — |
| 2023 | — | — | -US$53.13M | -US$58.98M | — |
| 2022 | — | — | -US$63.07M | -US$66.05M | — |
| 2021 | — | — | -US$51.73M | -US$53.16M | — |
Quarterly results
Data as of 2026-06-30
| Quarter | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| 2026-06-30 | — | -US$20.32M | — |
| 2026-03-31 | — | -US$4.45M | — |
| 2025-12-31 | — | -US$23.06M | — |
| 2025-09-30 | — | -US$13.29M | — |
| 2025-06-30 | US$1.51M | -US$20.15M | — |
| 2025-03-31 | — | -US$46.36M | — |
| 2024-12-31 | — | US$17.38M | — |
| 2024-09-30 | — | US$5.69M | — |
Sources
- Source: SEC EDGAR company facts
Charts, drawing tools, and the P/E calculator are in the app, free to use.